Research and Markets: Competitor Analysis: Her2 antibodies – trastuzumab biosimilars and biobetters/biosuperiors

April 3, 2013 9:24 AM

Research and Markets has announced the addition of the “Competitor Analysis: Her2 Antibodies – Trastuzumab Biosimilars and Biobetters/Biosuperiors” report to their offering.

The present Competitive Intelligence Report about Her2 Antibodies – Trastuzumab Biosimilars and Biobetters/Biosuperiors provides a competitor evaluation in the field of recombinant antibodies targeting Her2 used to treat Her2 positive breast and gastric cancer as of November 2012.

The recombinant humanized anti-Her2 antibody trastuzumab (Herceptin) from Genentech/Roche is among the world’s commercially most successful antibodies (2011 sales of over US$ 5.5 bln). Herceptin is approved and marketed for Her2 positive breast and gastric cancer. Genentech and Roche are still expanding the indication label of trastuzumab and have developed 2nd and 3rd generation Her2 antibodies.

The commercial attractiveness of trastuzumab has stimulated many companies to create and develop next generation anti-Her2 monoclonal antibodies (mabs) with improved properties compared with the humanized antibody trastuzumab. These Biosuperior antibodies include antibody-drug conjugates, bispecific antibodies and engineered Her2 antibodies. The forthcoming patent expiry for Herceptin has boosted interest in and activties for developing biosimilar copies with the most advanced projects already in phase III. At present, there are at least seven Herceptin biosimilar antibodies in clinical development and further 15 in preclinical R&D.

The report includes a compilation of currently active projects in development of Her2 targeting antibodies for treatment of Her2 positive breast and gastric cancer. In addition, the report lists company-specific R&D pipelines of Her2 antibodies.


Source: Research and Markets press release

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)

Latest News on Biosimilar News

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?


Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!